Current and Developing Liquid Biopsy Techniques for Breast Cancer

被引:33
作者
Wu, Hsing-Ju [1 ,2 ,3 ]
Chu, Pei-Yi [4 ,5 ,6 ,7 ,8 ]
机构
[1] Show Chwan Mem Hosp, Res Assistant Ctr, Changhua 500, Taiwan
[2] Chang Bing Show Chwan Mem Hosp, Dept Med Res, Changhua 505, Taiwan
[3] Natl Changhua Univ Educ, Dept Biol, Changhua 500, Taiwan
[4] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 402, Taiwan
[5] Show Chwan Mem Hosp, Dept Pathol, Changhua 500, Taiwan
[6] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei 242, Taiwan
[7] Chung Chou Univ Sci & Technol, Dept Hlth Food, Changhua 510, Taiwan
[8] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan
关键词
breast cancer; liquid biopsy; circulating tumor cells; circulating tumor DNA; microRNA; extracellular vesicles; CIRCULATING TUMOR DNA; CELL-FREE DNA; EXTRACELLULAR VESICLES; NEOADJUVANT CHEMOTHERAPY; CLINICAL-IMPLICATIONS; ABERRANT METHYLATION; MUTATION DETECTION; PROGNOSTIC VALUE; SERUM MICRORNA; NUCLEIC-ACIDS;
D O I
10.3390/cancers14092052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Breast cancer is the most common cancer and leading cause of death worldwide. Therefore, it is important to diagnose and treat breast cancer early. Current diagnostic methods include mammography and tissue biopsy; however, they have limitations. Liquid biopsy is a less invasive tool for diagnosis. In this review, we summarize and focus on the recent discoveries on liquid biopsy and development of detection techniques. Breast cancer is the most commonly diagnosed cancer and leading cause of cancer mortality among woman worldwide. The techniques of diagnosis, prognosis, and therapy monitoring of breast cancer are critical. Current diagnostic techniques are mammography and tissue biopsy; however, they have limitations. With the development of novel techniques, such as personalized medicine and genetic profiling, liquid biopsy is emerging as the less invasive tool for diagnosing and monitoring breast cancer. Liquid biopsy is performed by sampling biofluids and extracting tumor components, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free mRNA (cfRNA) and microRNA (miRNA), proteins, and extracellular vehicles (EVs). In this review, we summarize and focus on the recent discoveries of tumor components and biomarkers applied in liquid biopsy and novel development of detection techniques, such as surface-enhanced Raman spectroscopy (SERS) and microfluidic devices.
引用
收藏
页数:33
相关论文
共 228 条
[1]   Rapid and efficient capturing of circulating tumor cells from breast cancer Patient's whole blood via the antibody functionalized microfluidic (AFM) chip [J].
Abdulla, Aynur ;
Zhang, Zhianan ;
Ahmad, Khan Zara ;
Warden, Antony R. ;
Li, Hengyu ;
Ding, Xianting .
BIOSENSORS & BIOELECTRONICS, 2022, 201
[2]   Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients [J].
Aguilar-Mahecha, Adriana ;
Lafleur, Josiane ;
Brousse, Susie ;
Savichtcheva, Olga ;
Holden, Kimberly A. ;
Faulkner, Nathan ;
McLennan, Graham ;
Jensen, Taylor J. ;
Basik, Mark .
CANCERS, 2021, 13 (06) :1-12
[3]   Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies [J].
Akers, Johnny C. ;
Gonda, David ;
Kim, Ryan ;
Carter, Bob S. ;
Chen, Clark C. .
JOURNAL OF NEURO-ONCOLOGY, 2013, 113 (01) :1-11
[4]   Challenges and achievements of liquid biopsy technologies employed in early breast cancer [J].
Alba-Bernal, Alfonso ;
Lavado-Valenzuela, Rocio ;
Emilia Dominguez-Recio, Maria ;
Jimenez-Rodriguez, Begona ;
Isabel Queipo-Ortuno, Maria ;
Alba, Emilio ;
Comino-Mendez, Inaki .
EBIOMEDICINE, 2020, 62
[5]   Liquid biopsy in breast cancer: A comprehensive review [J].
Alimirzaie, Sahar ;
Bagherzadeh, Maryam ;
Akbari, Mohammad R. .
CLINICAL GENETICS, 2019, 95 (06) :643-660
[6]   Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [J].
Alix-Panabieres, Catherine ;
Pantel, Klaus .
CANCER DISCOVERY, 2016, 6 (05) :479-491
[7]   Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].
Andre, F. ;
Ciruelos, E. M. ;
Juric, D. ;
Loibl, S. ;
Campone, M. ;
Mayer, I. A. ;
Rubovszky, G. ;
Yamashita, T. ;
Kaufman, B. ;
Lu, Y-S ;
Inoue, K. ;
Papai, Z. ;
Takahashi, M. ;
Ghaznawi, F. ;
Mills, D. ;
Kaper, M. ;
Miller, M. ;
Conte, P. F. ;
Iwata, H. ;
Rugo, H. S. .
ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217
[8]  
Andre F, 2020, J CLIN ONCOL, V38
[9]   Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].
Andre, Fabrice ;
Ciruelos, Eva ;
Rubovszky, Gabor ;
Campone, Mario ;
Loibl, Sibylle ;
Rugo, Hope S. ;
Iwata, Hiroji ;
Conte, Pierfranco ;
Mayer, Ingrid A. ;
Kaufman, Bella ;
Yamashita, Toshinari ;
Lu, Yen-Shen ;
Inoue, Kenichi ;
Takahashi, Masato ;
Papai, Zsuzsanna ;
Longin, Anne-Sophie ;
Mills, David ;
Wilke, Celine ;
Hirawat, Samit ;
Juric, Dejan .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940
[10]   EMT: 2016 [J].
Angela Nieto, M. ;
Huang, Ruby Yun-Ju ;
Jackson, Rebecca A. ;
Thiery, Jean Paul .
CELL, 2016, 166 (01) :21-45